SOUTH
SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 6, 2023
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:
EPIX), a clinical-stage pharmaceutical company focused on
developing novel therapies for the treatment of prostate cancer,
today announced that it has entered into an Open Market Sale
AgreementSM (the "ATM Sales Agreement") with Jefferies LLC,
effective as of November 3, 2023.
Under the ATM Sales Agreement, ESSA may sell its common shares in
the capital of the Company from time to time for up to US$50.0 million in aggregate sales proceeds. No
offers or sales of common shares will be made in Canada, to anyone known by Jefferies, LLC to
be a resident of Canada or on or
through the facilities of any stock exchange or trading markets in
Canada.
The offering of common shares is being made pursuant to a
prospectus supplement to the Company's registration statement on
Form S-3, including a base prospectus, filed with the United States
Securities and Exchange Commission (the "SEC"). Before you invest
in the securities offered, you should read the prospectus
supplement relating to and describing the terms of the offering and
the related registration statement on Form S-3 and other documents
that ESSA has filed with the SEC for more complete information
about ESSA and the offering. You may get these documents for free
by visiting EDGAR on the SEC website at www.sec.gov. Alternatively,
copies of the prospectus supplement relating to the offering may be
obtained, when available, from: Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone:
1-877-821-7388 or by emailing
Prospectus_Department@jefferies.com
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
may there be any sale of the securities being offered in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on
developing novel and proprietary therapies for the treatment of
patients with prostate cancer.
Forward-Looking Statement
Disclaimer
This release contains certain information which, as presented,
constitutes "forward-looking information" within the meaning of the
Private Securities Litigation Reform Act of 1995 and/or applicable
Canadian securities laws. Forward-looking information involves
statements that relate to future events and often addresses
expected future business and financial performance, containing
words such as "anticipate", "believe", "plan", "estimate",
"expect", and "intend", statements that an action or event "may",
"might", "could", "should", or "will" be taken or occur, or other
similar expressions and includes, but is not limited to, statements
regarding expectations regarding our offering from time to time of
common shares in the capital of the Company pursuant to the ATM
Sales Agreement.
Forward-looking statements and information are subject to
various known and unknown risks and uncertainties, many of which
are beyond the ability of ESSA to control or predict, and which may
cause ESSA's actual results, performance or achievements to be
materially different from those expressed or implied thereby. Such
statements reflect ESSA's current views with respect to future
events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by ESSA as of the date of such statements,
are inherently subject to significant medical, scientific,
business, economic, competitive, political and social uncertainties
and contingencies. In making forward looking statements, ESSA may
make various material assumptions, including but not limited to (i)
the accuracy of ESSA's financial projections; (ii) obtaining
positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; and (iv) general business, market and
economic conditions.
Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein
and in ESSA's Annual Report on Form 10-K dated December 13, 2022, under the heading "Risk
Factors", a copy of which is available on ESSA's profile on EDGAR
at www.sec.gov and on SEDAR+ at www.sedarplus.ca, and as otherwise
disclosed from time to time on ESSA's EDGAR and SEDAR+ profiles.
Forward-looking statements are made based on management's beliefs,
estimates and opinions on the date that statements are made and
ESSA undertakes no obligation to update forward-looking statements
if these beliefs, estimates and opinions or other circumstances
should change, except as may be required by applicable United States and Canadian securities laws.
Readers are cautioned against attributing undue certainty to
forward-looking statements.
View original
content:https://www.prnewswire.com/news-releases/essa-pharma-enters-into-at-the-market-equity-offering-sales-agreement-301979221.html
SOURCE ESSA Pharma Inc